An observational study in Early Gastric Cancer and Gastric Adenoma, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Samsung Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Stomach Neoplasms by Samsung Medical Center — 6 open to participants now, 7 under way, none of them phase 3. Stomach Neoplasms · Samsung Medical Center.
Among the 40 studies in Stomach Neoplasms by Samsung Medical Center, this one is one of 2 that started in 2020, is one of 8 observational ones, and was the 31st registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →6 of the 40 studies in Stomach Neoplasms by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 20+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 20+
Samsung Medical Center · Sites in Korea, Republic of
Healthy volunteers
Samsung Medical Center · Sites in Korea, Republic of
Ages 20–75
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 19 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 8
First in 2003; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,730 is above the median of 278 across 792 observational studies indexed under Stomach Neoplasms.
Median enrollment 66 across the 32 interventional studies, 375 across the 8 observational. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 40 studies in Stomach Neoplasms by Samsung Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Because advanced gastric cancer shows poor prognosis, it is important to detect early gastric cancer or precancerous gastric adenoma patients who have a cure rate of 95% or more. Moreover, a large part of early gastric cancer can be completely resected by endoscopic resection, thus ensuring a very high quality of life for patients. However, there are currently no markers that can be used for diagnosis of early gastric cancer or gastric adenoma. In addition, the biggest problem after endoscopic resection of early gastric cancer is metachronous recurrence of the cancer, which requires repeated endoscopic resection or additional surgical gastrectomy. However, there are no discovered markers for prediction of recurrence.
Liquid biopsy is a method of obtaining body fluids such as gastric juice or effusion through an endoscopic inlet during gastroscopy or colonoscopy and blood. Based on the advanced analysis method, liquid biopsy reveals more genetic information than tissue biopsy. Therefore, it is highly likely to become an essential factor in future personalized medicine. Therefore, this study was designed to identify whether tumor's molercular profiling based on tissue or blood could be used for prediction of prognosis and diagnosis of early gastric cancer and precancerous gastric adenoma.
Suitability of tmor samples
: Tumor areas (> 60%) are dissected under microscopy from 4-μm-thick unstained sections by comparison with an H\&E stained slide, and genomic DNA was extracted using a Qiagen DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. After extraction, we measured concentrations and 260/280 and 260/230 nm ratios using a spectrophotometer (ND1000, Nanodrop Technologies, ThermoFisher Scientific, MA, USA). Each sample was then quantified with an Qubit fluorometer (Life Technologies, Carlsbad, CA, USA). Samples of genomic DNA with more than 10 ng measured by the Qubit fluorometer were subjected to AmpliSeq library preparation. To identify "druggable" CNVs, we used a 21-gene nCounter CNV assay.
Method of tumor molecular profiling
Immunohistochemistry
: RET, ATM, PD-L1, FGFR2, MLH, EGFR, ALK, ROS, TRKA. MET, HER2, PTEN loss (EGFR,CCNEI in selected cases)
Cancer Scan
: targeted deep sequencing at Samsung Genome Institute
: Illumina HiSeq2000/2500-based, MiSeq NGS targeted sequencing
A total of 1730 patients with early gastric cancer and precancerous gastric adenoma will be enrolled. Based on previous studies, approximately 20% of the subjects are expected to have mutations. In this study, metachronous tumor recurrence rate between the mutation group and non-mutation group will be compared. In general, metachronous tumor recurrent rate after endoscopic resection for early gastric cancer or gastric ademona is reported to be 6%-10%. In this study, the metachronous tumor recurrence rate is expected to be 10% and 5% in the mutation and non-mutation group, respectively. When a two-sided chi-square test with a power of 5% and 90% type 1 error is performed, 346 and 1384 subjected are expected to be included in the mutation group and non-mutation group, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Identify biomarkers for differential diagnosis between early gastric cancer and precancerous adenoma.
Tumor's moleular profiling is assessed by following method: 1. Ion Torrent PGM Amplieq Canccer Panel 2.0 2. Nanostring copy number variation (CNV) panel 3. Immunohistochemistry: RET, ATM, PD-L1, FGFR2, MLH, EGFR, ALK, ROS, TRKA. MET, HER2, PTEN loss (EGFR,CCNEI in selected cases) 4. Illumina HiSeq2000/2500-based, MiSeq NGS targeted sequencing 5. ASFA™ Spotter
Time frame: From the date of initial treatment until the date of first recurrence or up to 2 years, whichever came first.
Indentify prognostic biomarkers for predicting recurrence of early gastric cancer and precancerous adenoma lesion.
Comparison of tumor's molecular profile between the cases of recurrence and non-recurrence. Tumor's moleular profiling is assessed by following method: 1. Ion Torrent PGM Amplieq Canccer Panel 2.0 2. Nanostring copy number variation (CNV) panel 3. Immunohistochemistry: RET, ATM, PD-L1, FGFR2, MLH, EGFR, ALK, ROS, TRKA. MET, HER2, PTEN loss (EGFR,CCNEI in selected cases) 4. Illumina HiSeq2000/2500-based, MiSeq NGS targeted sequencing 5. ASFA™ Spotter
Time frame: From the date of initial treatment until the date of first recurrence or up to 2 years, whichever came first.
Change in the tumor's molecular profile on serial biopsies at the time of initial treatment, 2 months after treatment, 1 year after treatment, or recurrence.
The method of tumor's moleular profiling is same as the above.
Time frame: From the date of initial treatment until the date of first recurrence or up to 2 years, whichever came first.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2020 (actual). Primary completion is estimated for Dec 2029, 108 months after the start.
Of 324 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 108 months is above that.
Counting every sponsor, half of 367 studies reached it within 54 months; a quarter within 29 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.